Introduction: As a major health problem, urolithiasis constitutes the third most common disease of the urinary tract, affecting 2-3% of the population, with a high recurrence rate of almost 50% [1]. The incidence of ureteric stones is increasing all over the world. This increase is seen across age, sex, and race. Changes in diet pattern and global warming seem to influence these trends [2]. Recent reviews of published papers suggest that 90% stones of less than 5 mm and 15% stones of sizes between 5mm-8mm will pass spontaneously [3]. For stones less than 5 mm size recommended management includes analgesic, antibiotics and hydration therapy. With medical expulsive therapy, in which Tamsulosin is the main stay, spontaneous passage of stone up to 10 mm has been reported [4].

Among our patients 61.46% of ureteral stones are located in the lower third of the ureter. Similar observations have been made by other authors also. In the last 20 years ureteral stones treatment modalities have changed radically and MET have become a part of the standard protocol for treatment of smaller size stones in the lower third of the ureter. It increases the expulsion rate and decreases the expulsion time, thereby reducing the cost and lost working days [5]. Stones up to 4 mm size are expelled in almost all cases. Spontaneous expulsion rate for 4-6 mm stones is about 25% and over 8 mm size are rarely expelled [6]. Different procedures have been recommended for stones of greater than 5 mm size. Stones up to 9.5 mm have been successfully expelled with MET, the largest size stone being 1.4 cm [7]. The eventual factors for spontaneous expulsion of ureteral stones size, location, number, spasm in ureteral smooth muscle, mucosal edema, inflammation and ureteral anatomy.

The basis of pharmacotherapy is different for different drug groups. In the case of alpha blockers, the human ureter contains predominantly alphas receptors which are further classified as alpha 1 and alpha 2 receptors. In turn alpha 1 receptors which are divided into subtypes on the bases of their selectivity. Alpha 1a (proximal urethra, prostate, bladder outlet), alpha 1b (smooth muscles of vessels) and alpha 1d (detrusor, lower ureter). Specifically those of alpha type, serve an important role in lower urethral physiology. Nor epinephrine is the main alpha-agonist which exerts positive chronotropic effect on the ureter, thereby
increasing peristaltic frequency. Positive chronotropic effect, increases muscle tone and at high doses may lead to complete ureteral obstruction. In ureter alpha adrenergic receptor antagonists inhibit basal tone and also decrease peristaltic frequency and amplitude. Consequently intravesical pressure decreases, there is an increase in fluid transport ability which increases the bolus of urine thus exerting pressure above the stone, at the same time peristalsis and intravesical pressure decrease below the stone. The net effect is an increase in intra ureteral pressure gradient around the stone which ultimately results in stronger expulsive force.

Urolithiasis is one of the commonest urological disorders in our state. Considering the economic condition of the state and various complications of non conservative treatments (ESWL/ureteroscopic lithotripsy/surgery), the MET for ureteric stones can be the preferable, promising and economic choice of treatment. SOADS regime represents a non invasive and cost-effective alternative to interventional approaches with fewer side effects like hypotension, asthenia and retro grade ejaculation.

Materials and Methods

This study was non-interventional and prospective cross sectional conducted in the Urological Departments of Super speciality hospital GMC, Srinagar and Kidney hospital & Research centre Srinagar, Kashmir, J&K, India from January 2008 to December 2017. A total of 3000 patients were enrolled during these Nine (9) years, both sexes who were over above 9 years up to 85 yrs (Table 1&2), having single stone size less than or equal to 9mm reporting within 2 days of colic. Patients with pregnancy, breast feeding, contraindication to SOADS regime, complication needing surgery, renal/Liver failure, solitary kidney, Bilateral ureteric stones were excluded from the study. An explanation was given to the patients including the reason why he or she was prescribed the SOADS regime, the possible side effects and effectiveness of the drug and their written approval was taken.

Table 1: Showing male/female ratio.

| S. no | Sex  | Number | % Percentage |
|-------|------|--------|--------------|
| 1.    | Male | 1977   | 65.9%        |
| 2.    | Female | 1023  | 34.1%        |

Table 2: Showing Age Groups.

| 1. | Age Group | Number | % Percentage |
|----|-----------|--------|--------------|
| 1. | 9 yrs - 18 yrs | 419 | 13.96 % |
| 2. | 19 yrs - 30 yrs | 1001 | 33.36 % |
| 3. | 31 yrs - 50 yrs | 894 | 29.80 % |
| 4. | 51 yrs - 70 yrs | 558 | 18.62 % |
| 5. | 71 yrs - 85 yrs | 128 | 04.26 % |
| Total |         | 3000 | 100 % |

All patients who reported within 1-2 days of ureteric colic were examined, and subjected to Haemogram, KFT, Urine examination, Ultrasound and NCCT Scan (Figure 1 & 2) to document ureteric calculi at the time of colic with respect to location, side and size of the stone. Age and sex of the patient was noted down and SOADS regime was started for a period of 4 weeks maximum after which this MET was stopped. The routine follow up examination were performed, using the same tools to evaluate the success of the treatment after every week till 4 weeks of study period. Patients were instructed to discontinue the study medication after spontaneous stone expulsion and date of expulsion is to be recorded. For patients without stone in urinary tract on final USG/NCCT but unnoticed stone expulsion, the date of last positive stone status is to be recorded (Figure 3). For the children the dosage of the SOADS regime was half the dosage. Two - three litres of fluid which consists of Lemon juices, Oranges juices and clear water or Tea. This regime was continued for 2 weeks after which again assessment was made and if the stone did not pass then it was continued for another 2 weeks. Treatment was considered successful when stone was expelled within 4 weeks. After 4 weeks, patients who did not pass the stone were advised to undergo minimally invasive surgery depending upon the stone size and location.
Results

The diagnosis of the ureteric stone was established in 3000 patients, by ultrasound and NCCT Abdomen & Pelvis. Out of 3000 pts, there were 1977 males and 1023 females with age range from 9 years to 85 years. Out of 3000 pts, 2550 pts (85%) passed stone with SOADS regime within 4 weeks. Of 2550 pts, 1657 (65%) passed stone within 2 weeks of therapy and rest 893 pts (35%) passed stone within 4 weeks of therapy (Table 3-5). 4-6 mm stone size, comprises about 1814 pts (60.46 %), while 7-9 mm comprises about 1186 pts (39.53 %). Lower the size greater the chance of the stone to pass. Stones at UVJ and lower ureter had higher incidence of passage than stones in the upper ureter. Sex had no impact on stone passage. Right sided stones (1553/1678) had increase chance of passage than left (997/1322). In patients of unilateral obstruction, there was 10 mmHg increases in both systolic/diastolic blood pressure. Uric acid stone had increased chance of passage than calcium oxalate monohydrate calculi. Fluids like Lemon, Orange and Tea consumption were associated with increased stone passage. NCCT abdomen/Pelvis was the best investigation to confirm the presence of calculi with respect to size, composition, side, location and upper tract dilatation.

Table 3: SOADS regime.

| Tab Alfuzosin 10 mg at bed time daily once |
| Tab Ofloxacin 200 mg BD daily |
| Tab Drotaverine hydrochloride 80 mg + Tab Mefenamic Acid 250 mg one tab BD daily |
| Tab Spirinolactone 25 mg daily once after breakfast |
| Syrup Potassium magnesium citrate , 2 tsf with one glass of water TDS |

Table 4: Passed stone within 4 weeks of therapy.

| Stone Characteristics | Within 2 Weeks | Between 2-4 Weeks | Within 4 Weeks | Did not Pass Stone | P-Value |
|-----------------------|---------------|------------------|----------------|--------------------|---------|
| Stone Size (mm)       | Number        | %                | Number         | %                | Number  | %    |
| 4 mm                  | 680           | 79.6             | 154            | 18.0              | 834     | 97.7 | 20  | 2.3  |
| 5 mm                  | 371           | 66.5             | 120            | 21.5              | 491     | 88.0 | 67  | 12.0 |
| 6 mm                  | 285           | 70.9             | 47             | 11.7              | 332     | 82.6 | 70  | 17.4 |
| 7 mm                  | 189           | 37.1             | 235            | 46.1              | 424     | 83.1 | 86  | 16.9 |
| 8 mm                  | 93            | 20.7             | 269            | 59.9              | 362     | 80.6 | 87  | 19.4 |
| 9 mm                  | 39            | 17.2             | 68             | 30.0              | 107     | 47.1 | 120 | 52.9 |
| Location of stone     |               |                  |                |                   |         |      |     |      |
| Upper ureter          | 99            | 23.7             | 202            | 48.3              | 301     | 72.0 | 146 | 34.9 |
| Mid ureter            | 316           | 42.8             | 291            | 39.4              | 607     | 82.2 | 130 | 17.6 |
| Lower ureter          | 651           | 66.4             | 224            | 22.8              | 875     | 89.2 | 93  | 9.5  |
| UVJ Calculi           | 591           | 68.5             | 176            | 20.4              | 767     | 88.9 | 81  | 9.4  |

Discussion

Urolithiasis is a common problem in northern part of India. Most of these patients also have ureteric calculi of varying sizes. Most of the small ureteric calculi usually pass spontaneously but with severe pain during expulsion and microscopic haematuria. In recent years, significant advances have been made in every medical field, ESWL and ureteroscopy have been widely used for the treatment of ureteric stones, however these procedures are not risk free [8]. MET is aimed at facilitating the passage/expulsion of ureteric stone with minimal symptoms. The main factors associated with obstruction by stones are ureteral smooth muscle spasm, mucosal edema, pain and infection. Medical therapy is aimed to addresses these factors. Various drug combinations have been described. Drugs like corticosteroids, hormones, NSAID, calcium channel blockers and alpha-1 adrenergic blockers have been evaluated. Encouraging results have been reported with
use of calcium channel blockers and alpha-1 adrenergic blockers. Calcium channel blockers suppress smooth muscle contraction and reduce ureteral spasm, whereas alpha-1 adrenergic blockers decrease ureteral muscle tone and frequency of peristalsis [9]. Corticosteroids reduce inflammatory reaction and sub mucosal oedema in the vicinity of stone [10].

Table 5: Patient/stone characteristics.

| Patient/Stone Characteristic | Number | Percentage |
|------------------------------|--------|------------|
| **Sex**                      |        |            |
| Male                         | 1977   | 65.9       |
| Female                       | 1023   | 34.1       |
| **Age ( Years )**            | 36.3 (9-85) |        |
| **Time to Pass Stone**       |        |            |
| Within 2 weeks               | 1657   | 55.2       |
| 2-4 weeks                    | 893    | 29.8       |
| Within 4 weeks               | 2550   | 85.0       |
| Did not pass stone           | 450    | 15.0       |
| **Stone Size ( mm )**        |        |            |
| 4                            | 854    | 28.5       |
| 5                            | 558    | 18.6       |
| 6                            | 402    | 13.4       |
| 7                            | 510    | 17.0       |
| 8                            | 449    | 15.0       |
| 9                            | 227    | 7.6        |
| **Location of Stone**        |        |            |
| Upper ureter                 | 418    | 13.9       |
| Mid ureter                   | 738    | 24.6       |
| Lower ureter                 | 981    | 32.7       |
| UVJ Calculi                  | 863    | 28.8       |
| **Laterality**               |        |            |
| Right                        | 1678   | 55.9       |
| Left                         | 1322   | 44.1       |

In our study 85% (2550 out of 3000 pts) of patients passed stone with SAODS regime within 4 weeks. A meta-analysis of nine randomised clinical trials has compared calcium channel blockers or alpha-1 blockers with or without corticosteroids against placebo or no treatment. This has shown that patients treated with MET had a 65% of greater chance of spontaneous passage of stone than the control group. In this analysis there was no significant benefit of adding corticosteroid with calcium channel or alpha-1 blockers which was also proved in our study as we exclude corticosteroid in our group. Cooper and associates treated 70 patients having ureteral calculi and found that addition of nifedipine, prednisone, acetaminophen and antibiotics to standard medical therapy resulted in higher stone passage rate and fewer workday lost, emergency visits and surgical interventions [9].

**Conclusion**

A conservative approach should be considered as an option in the management of ureteric calculi in patients who present within 1-2 days of colic in uncomplicated, unilateral and stone size of less than 10mm with SAODS regime as an outpatient treatment for maximum of 4 weeks after which they should be advised other viable options.

**Conflict of Interest**

None.

**Acknowledgement**

None.

**References**

1. Yencilek F, Erturhan S, Onur C, Koyuncu H, Erol B, et al. (2010) Does Tamsulosin change the Management of proximally located Ureteric stones? Urol Res 38(3): 195-199.
2. Sierakowski R, Finlayson B, Landes RR, Finlayson CD, Sierakowski N (1978) The frequency of Urolithiasis in hospital discharge diagnosis in the United States. Invest Urol 15(6): 438-441.
3. Seitz C, Liatsikos E, Porpiglia F, Tseliulis HG, Zwerdel U (2009) Medical therapy to facilitate the passage of stones: What is the evidence? Eur Urol 56(3): 455-471.
4. Gervenakov I, Fillo J, Mardiak J, Kopecy M, Sminja L, et al. (2002) Speedy elimination of ureterolithiasis in lower part of ureters with the alpha1blocker-Tamsulosin. Int Urol Nephrol 34(1): 25-29.
5. Hollingsworth JM, Rogers MA, Kaufman SR, Bradford TJ, Saint S, et al. (2006) Medical therapy to facilitate urinary stone passage: a meta-analysis. Lancet 368(9542): 1171-1179.
6. Ueno A, Kawamura T, Ogawa A, Takayasu H (1977) Relation of spontaneous passage of ureteral calculi to size. Urology 10(6): 544-546.
7. Carstensen HE, Hansen TS (1973) Stones in the ureter. Acta Chir Scand Suppl 433: 66-71.
8. Lotan Y, Gettman MT, Roehrborn CG, Cadeddu JA, Pearl MS (2002) Management of ureteric calculi: A cost comparison and decision making analysis. J Urol 167(4): 1621-1629.
9. Cooper JT, Stack GM, Cooper TM (2000) Intensive medical management of ureteral calculi. Urology 56(4): 575-578.
10. Tilkav M, Bhamare N (2012) Progesteron Hydrotherapy in Management of Small, Mid and Lower ureteric calculi. International Journal of Recent Trends in Science and Technology 4: 90-93.